Category: Cooley Alerts

Cooley Alert: Agreements Involving Biosimilars Must Be Reported to FTC and DOJ Under New Law

Biologic drug makers will soon have to alert the Federal Trade Commission (FTC) and the U.S. Department of Justice (DOJ) of agreements, including patent litigation settlements, they reach with biosimilar applicants. The new reporting requirement is part of the Patient Right to Know Drug Prices Act, which President Trump signed into […]

Cooley LLP Alerts | FTC Enforcement Powers Limited in LabMD Data Security Case

Source: https://www.cooley.com/ftc-enforcement-limited-in-labmd-data-security-case

Cooley LLP Alerts | China Piloting Drug Marketing Authorization Holder System

Source: Cooley LLP | Media | Alerts | China Piloting Drug Marketing Authorization Holder System

Cooley Alerts | No More Safe Harbor: What Should Life Sciences and Biotech Companies Be Doing to Transfer Data to the US?

Source: Cooley LLP | Media | Alerts | No More Safe Harbor: What Should Life Sciences and Biotech Companies Be Doing to Transfer Data to the US?

Resource Launch: Key Considerations for Health Care Fraud Government Investigations/Inquiries

Cooley is excited to release a new resource for health care and life sciences companies: Key Considerations for Health Care Fraud Government Investigations/Inquiries. This quick reference documents provides a list of steps that companies should consider taking before a government investigation/inquiry occurs, and key steps to take if a becomes aware of a […]